$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Cochlear implantation is the only treatment in clinical use that restores the function of a sensory organ. Currently, cochlear implantation is applied to treat severe-to-profound sensorineural hearing loss in children and adults. The cochlear implant (CI) system consists of an implantable internal device that is combined with an external sound processor. The internal device is inserted during surgery through the mastoid cavity. The facial recess is opened to gain access to the middle ear and cochlea. The electrode array is inserted into the cochlea through the posterior tympanotomy and round window of the cochlea. The electrode array provides the electric stimulation by bypassing defective outer and inner hair cells and directly stimulating the auditory nerve's ganglion cells.
It has been demonstrated that the preservation of the integrity of the inner ear structures after CI surgery may contribute to more favorable hearing outcomes in comparison to electrode insertions, which can cause structural damage to the inner ear1,2. This has led to the development of more delicate surgical techniques and thinner, more flexible, and thus, less traumatic electrode arrays. These developments have contributed to improved hearing outcomes, leading to an expansion of the indications for CI rehabilitation. Patients with high-frequency (>1.5 kHz) severe hearing loss may also benefit from cochlear implantation, especially when their natural hearing in the low frequencies can be preserved (<1 kHz). Low-frequency hearing after surgery makes it possible for the patient to benefit from electro-acoustic stimulation (EAS)3,4. The EAS is a combination of electric stimulation to high-frequency areas of the cochlea, which are located in the basal parts of the cochlea, and acoustic amplification for the preserved low-frequency areas (typically 125-500 Hz) in the apical parts of the cochlea.
The best results in hearing preservation (HP) surgery have been achieved with shorter electrode arrays, specifically designed for EAS candidates4,5,6. There may be one major drawback associated with the short electrode arrays-the loss of residual hearing (either after surgery or subsequently). The patient may ultimately benefit from a longer electrode array that covers a broader range of frequencies, especially in cases where there has been an unfortunate loss of residual hearing5,7. Recently, the introduction of the partial insertion of the longer lateral-wall electrode in patients with moderate hearing loss at higher frequencies and normal or mild hearing loss at lower frequencies has created the option for initial shallow insertion in EAS candidates, but it also facilitates deeper insertion with the same array if the residual hearing is lost8.
Electrocochleography (ECochG) is a method that can be used to monitor cochlear function during cochlear implantation, and it has been increasingly exploited in clinical use. Currently, the three leading CI manufacturers provide a clinically approved tool, or at least a research tool, for intracochlear intraoperative ECochG measurements. One provides an all-in-one solution with the stimulation and response recording integrated into one tool, while the tools provided by the other manufacturers require a separate stimulator. ECochG measures the electrophysiological response from the inner ear and the auditory nerve to an acoustic stimulus. It seems that the amplitudes of the ECochG responses measured during the electrode insertion may predict postoperative hearing preservation. Thus, intraoperative ECochG seems to represent a promising tool to provide information that enables the prevention of trauma9,10,11,12. Active research and the increased clinical interest in assessing intraoperative ECochG measurements have raised the question of how to analyze the ECochG responses objectively and how to react to the changes in the amplitude of the response during insertion.
The feasibility and benefits of CI surgery under local anesthesia have been reported in several studies13,14,15,16. CI candidates with significant comorbidities can be operated on under local anesthesia, thus avoiding the risks related to general anesthesia. General anesthesia is associated with an increased risk of cognitive deterioration, especially in elderly patients, and it has also been associated with greater mortality in these groups17. When CI surgery is performed under local anesthesia, the recovery from the operation is faster, and, thus, the patient spends less time in the hospital as compared to with a similar operation performed under general anesthesia14,15,18,19. It has also been proposed that patients with residual hearing could be able to monitor their hearing during the insertion, which may guide the surgeon during the insertion of the CI electrode and avoid intracochlear trauma14.
We recently compared ECochG and subjective sound perception as indicators of hearing preservation in CI surgery under local anesthesia20. The results indicated a good prediction of hearing preservation with both methods, and similar patterns were observed between subjective reporting and ECochG monitoring. The patients' subjective feedback on sound perception, which was possible since only local anesthesia was in use, seemed to help minimize the risk of trauma to the inner ear during the insertion, even in cases when the ECochG responses could not be measured during the insertion.
Here, we present a state-of-the-art method for preserving residual hearing during CI surgery. We describe the treatment procedures, including the special considerations associated with performing the surgery under local anesthesia (e.g., ECochG) and subjective hearing monitoring.